Covered recipient · General Payments record
NEAL D SHORE
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$462,516.57
363 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $325,697.11 | 87 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $88,050.63 | 34 |
| Travel and Lodging | $37,596.55 | 85 |
| Food and Beverage | $6,272.28 | 154 |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $4,900.00 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NEAL D SHORE
NPI 1265423453 · CMS profile ID 11507
Allopathic & Osteopathic Physicians / Urology
MYRTLE BEACH, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1265423453?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NEAL D SHORE, NPI 1265423453, CMS profile ID 11507. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265423453?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). NEAL D SHORE, NPI 1265423453, CMS profile ID 11507. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265423453?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- NEAL D SHORE, NPI 1265423453, CMS profile ID 11507, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 8; records 151–200 of 363 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1265423453?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
363 matching records · $462,516.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 363.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $208.97 | 08/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628411363 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $6,160.00 | 08/08/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628436137 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $486.32 | 08/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628444435 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.24 | 08/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628445127 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $4,340.00 | 08/08/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628449349 | CMS |
| Integra GPO, LLC | $5,225.00 | 07/31/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 639791449 | CMS |
| Photocure Inc | $21.95 | 07/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686772191 | CMS |
| Janssen Biotech, Inc. | $500.00 | 07/22/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658714441 | CMS |
| GENZYME CORPORATION | $125.00 | 07/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694165503 | CMS |
| GENZYME CORPORATION | $6,615.00 | 07/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694165513 | CMS |
| GENZYME CORPORATION | $497.62 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694165515 | CMS |
| GENZYME CORPORATION | $638.15 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694165517 | CMS |
| GENZYME CORPORATION | $129.46 | 07/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694165519 | CMS |
| AstraZeneca UK Limited | $2,000.00 | 07/17/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685802845 | CMS |
| EMD Serono, Inc. | $13.14 | 07/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702999327 | CMS |
| PFIZER INC. | $11.49 | 07/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672476561 | CMS |
| ROCHESTER MEDICAL CORPORATION | $22.54 | 07/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699867029 | CMS |
| Clovis Oncology, Inc. | $23.68 | 07/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688689499 | CMS |
| Janssen Biotech, Inc. | $1,000.00 | 07/12/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658714437 | CMS |
| Astellas Pharma Global Development | $1,250.00 | 07/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 641930265 | CMS |
| AstraZeneca UK Limited | $1,500.00 | 07/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685178435 | CMS |
| GENZYME CORPORATION | $11.72 | 07/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694260559 | CMS |
| GENZYME CORPORATION | $351.11 | 07/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694260561 | CMS |
| GENZYME CORPORATION | $7,788.00 | 07/08/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694260563 | CMS |
| SANOFI-AVENTIS U.S. LLC | $4.22 | 07/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694138345 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $12.00 | 06/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628452415 | CMS |
| Integra GPO, LLC | $1,375.00 | 06/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 639791439 | CMS |
| Coloplast Corp | $106.10 | 06/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 696982683 | CMS |
| Genentech USA, Inc. | $12.07 | 06/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681304043 | CMS |
| PFIZER INC. | $1,500.00 | 06/24/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672433957 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $1,960.00 | 06/21/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628442581 | CMS |
| Janssen Global Services, LLC | $2,480.00 | 06/20/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 708407121 | CMS |
| Coloplast Corp | $11.84 | 06/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 696982681 | CMS |
| AbbVie, Inc. | $13.69 | 06/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648069545 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $64.14 | 06/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628481927 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $170.90 | 06/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628491849 | CMS |
| Ferring International Center SA | $43.62 | 06/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172413 | CMS |
| Ferring International Center SA | $37.00 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172415 | CMS |
| Ferring International Center SA | $20.00 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172417 | CMS |
| Ferring International Center SA | $14.00 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172419 | CMS |
| Ferring International Center SA | $14.00 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172421 | CMS |
| Ferring International Center SA | $10.00 | 06/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172423 | CMS |
| Janssen Research & Development, LLC | $1,100.00 | 06/13/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657419021 | CMS |
| Merck Sharp & Dohme Corporation | $150.00 | 06/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695643139 | CMS |
| Merck Sharp & Dohme Corporation | $5,500.00 | 06/13/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695643142 | CMS |
| Ferring International Center SA | $260.33 | 06/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172405 | CMS |
| Ferring International Center SA | $58.74 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172407 | CMS |
| Ferring International Center SA | $28.00 | 06/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172409 | CMS |
| Ferring International Center SA | $73.67 | 06/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172411 | CMS |
| Ferring International Center SA | $44.82 | 06/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655172401 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $65,684.95 | 57 |
| PY2025 | Principal investigator | $8,002,667.16 | 491 |
| PY2024 | Recipient | $57,211.77 | 44 |
| PY2024 | Principal investigator | $8,224,282.07 | 738 |
| PY2023 | Recipient | $60,749.73 | 82 |
| PY2023 | Principal investigator | $7,187,000.63 | 539 |
| PY2022 | Recipient | $36,625.82 | 60 |
| PY2022 | Principal investigator | $7,706,559.16 | 458 |
| PY2021 | Recipient | $24,657.08 | 55 |
| PY2021 | Principal investigator | $12,525,672.72 | 427 |
| PY2020 | Recipient | $21,543.29 | 45 |
| PY2020 | Principal investigator | $9,666,548.35 | 645 |
| PY2019 | Recipient | $16,681.00 | 65 |
| PY2019 | Principal investigator | $6,834,236.00 | 390 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
548 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,236.75 | 12/31/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401695 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,129.43 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett | No dispute reported | 06/30/2026 | 1232925155 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $22,662.47 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365 | No dispute reported | 06/30/2026 | 1232925771 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,491.28 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926743 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $12,091.56 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1232926917 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $22,150.54 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- | No dispute reported | 06/30/2026 | 1232927475 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $13,942.79 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1232927751 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $12,322.38 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 | No dispute reported | 06/30/2026 | 1232927983 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $194.33 | 12/31/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment | No dispute reported | 06/30/2026 | 1190313875 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,560.11 | 12/31/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190313881 |
| Principal investigator 1 | PFIZER INC. | $3,980.00 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228749938 |
| Principal investigator 1 | PFIZER INC. | $42,129.00 | 12/31/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | AN INTERVENTIONAL PHASE 1B2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA | No dispute reported | 06/30/2026 | 1228750366 |
| Principal investigator 1 | PFIZER INC. | $9,352.00 | 12/30/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228743871 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48,707.00 | 12/29/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175355106 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,169.00 | 12/29/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175355331 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $261,443.85 | 12/29/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926567 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,230.00 | 12/25/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175354949 |
| Principal investigator 1 | PFIZER INC. | $9,811.80 | 12/25/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER | No dispute reported | 06/30/2026 | 1228744909 |
| Principal investigator 1 | Exelixis Inc. | $5,966.35 | 12/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380318 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $57,779.50 | 12/23/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- | No dispute reported | 06/30/2026 | 1232927473 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $325.83 | 12/19/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411650 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $325.83 | 12/19/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411704 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,348.00 | 12/19/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175354611 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,666.50 | 12/18/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175354957 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/18/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726392 |
| Recipient | PFIZER INC. | $1,400.00 | 12/18/2025 | Covered Recipient Physician | MEVROMETOSTAT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727363 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/16/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228716589 |
| Principal investigator 1 | PFIZER INC. | $1,578.20 | 12/16/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228745907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,800.00 | 12/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354915 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,556.00 | 12/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175355365 |
| Principal investigator 1 | PFIZER INC. | $12,852.28 | 12/13/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228731471 |
| Principal investigator 1 | PFIZER INC. | $5,420.10 | 12/13/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228745138 |
| Principal investigator 1 | MEDIVATION LLC. | $17,581.20 | 12/11/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739104 |
| Principal investigator 1 | PFIZER INC. | $3,500.00 | 12/06/2025 | Non-covered Recipient Entity START San Antonio LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228730951 |
| Principal investigator 1 | PFIZER INC. | $6,300.00 | 12/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228723164 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 12/03/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401685 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 12/03/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401687 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 12/03/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401703 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $7,769.00 | 12/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892670 |
| Principal investigator 1 | Exelixis Inc. | $4,621.45 | 12/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,762.00 | 12/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,920.00 | 12/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354750 |
| Principal investigator 1 | Janssen Research & Development, LLC | $600.00 | 12/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175354861 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,322.00 | 12/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Gurin (BCG) | No dispute reported | 06/30/2026 | 1175355012 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,256.00 | 12/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175355339 |
| Principal investigator 1 | Laborie Medical Technologies Corp. | $1,101.00 | 12/01/2025 | Non-covered Recipient Entity CURC Carolina Urologic Research Ctr LLC | PINNACLE | No dispute reported | 06/30/2026 | 1250724520 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,040.48 | 12/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1190309294 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/01/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228718580 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,255.00 | 11/28/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175354597 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,917.00 | 11/28/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175354638 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,419.00 | 11/28/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175355182 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/27/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228717245 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 11/26/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409594 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,339.92 | 11/26/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409612 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 11/26/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409716 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $252.00 | 11/26/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409894 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $21,164.00 | 11/26/2025 | Non-covered Recipient Entity Carolina Urologic Research Center, Llc | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1235998390 |
| Principal investigator 1 | PFIZER INC. | $12,515.80 | 11/26/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228716511 |
| Principal investigator 1 | PFIZER INC. | $46,900.00 | 11/26/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF PF08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER | No dispute reported | 06/30/2026 | 1228739066 |
| Principal investigator 1 | PFIZER INC. | $9,163.70 | 11/25/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228737474 |
| Principal investigator 1 | PFIZER INC. | $1,785.22 | 11/25/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228739141 |
| Principal investigator 1 | PFIZER INC. | $1,200.00 | 11/24/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH | A STUDY OF INTRAVESICAL ENFORTUMAB VEDOTIN FOR TREATMENT OF PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER NMIBC | No dispute reported | 06/30/2026 | 1228730200 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,463.00 | 11/21/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175355064 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $471.75 | 11/19/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177 | No dispute reported | 06/30/2026 | 1190313877 |
| Principal investigator 1 | AstraZeneca UK Limited | $34,250.00 | 11/14/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | a randomized,double blind,placebo controlled,phase third study of adjuvant saruparib AZD5305 in patients with bracam localized high risk prostate cancer receiving radiotherapy with aqndrogen deprivation therapy evo par prostate | No dispute reported | 06/30/2026 | 1185542070 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 11/14/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401640 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 11/14/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $109.00 | 11/14/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270080 |
| Principal investigator 1 | PFIZER INC. | $1,432.60 | 11/14/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228716509 |
| Recipient | PFIZER INC. | $940.00 | 11/14/2025 | Covered Recipient Physician | DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726868 |
| Principal investigator 1 | PFIZER INC. | $1,556.08 | 11/13/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228730488 |
| Principal investigator 1 | PFIZER INC. | $71,276.60 | 11/13/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228738044 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $500.00 | 11/12/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection | No dispute reported | 06/30/2026 | 1249804320 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,483.00 | 11/10/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175354700 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/10/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228717249 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/10/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228718587 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,768.00 | 11/07/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175269938 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,979.00 | 11/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175355356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,520.00 | 11/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175355307 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $1,353.00 | 11/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection | No dispute reported | 06/30/2026 | 1249804294 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,036.00 | 11/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654637 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $900.00 | 11/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654807 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,036.00 | 11/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176654820 |
| Recipient | PFIZER INC. | $940.00 | 11/04/2025 | Covered Recipient Physician | DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $51.75 | 11/03/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | DS1062-328 | No dispute reported | 06/30/2026 | 1223365347 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $94.00 | 11/03/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | DS1062-328 | No dispute reported | 06/30/2026 | 1223365349 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $376.00 | 11/03/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | DS1062-328 | No dispute reported | 06/30/2026 | 1223365351 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,574.00 | 11/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175354652 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,121.00 | 11/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175354834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,336.00 | 11/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175354907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,000.00 | 11/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175354941 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,320.00 | 11/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175355300 |
| Recipient | PFIZER INC. | $330.00 | 11/03/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726822 |
| Principal investigator 1 | PFIZER INC. | $221,237.47 | 11/01/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228737663 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,363.62 | 10/28/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combin | No dispute reported | 06/30/2026 | 1190313879 |
| Recipient | PFIZER INC. | $620.00 | 10/24/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726748 |
| Principal investigator 1 | PFIZER INC. | $789.10 | 10/24/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228741832 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $762.30 | 10/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | No dispute reported | 06/30/2026 | 1242061241 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,722.00 | 10/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175354602 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $71,098.00 | 10/22/2025 | Non-covered Recipient Entity Carolina Urologic Research Center Llc | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225409028 |
| Recipient | Novartis Pharmaceuticals Corporation | $8,687.99 | 10/21/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291692 |
| Recipient | PFIZER INC. | $330.00 | 10/21/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228720175 |
| Recipient | PFIZER INC. | $330.00 | 10/21/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726798 |
| Principal investigator 1 | PFIZER INC. | $24,627.30 | 10/21/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228741471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,078.00 | 10/20/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175355199 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $7,050.00 | 10/20/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 | No dispute reported | 06/30/2026 | 1232927981 |
| Recipient | PFIZER INC. | $940.00 | 10/18/2025 | Covered Recipient Physician | MEVROMETOSTAT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726750 |
| Recipient | PFIZER INC. | $940.00 | 10/18/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726908 |
| Recipient | PFIZER INC. | $940.00 | 10/18/2025 | Covered Recipient Physician | DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727177 |
| Recipient | PFIZER INC. | $940.00 | 10/18/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727799 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 10/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401655 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 10/15/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401661 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,953.48 | 10/15/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409950 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,069.43 | 10/15/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410182 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,339.92 | 10/15/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410290 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $500.00 | 10/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection | No dispute reported | 06/30/2026 | 1249804257 |
| Principal investigator 1 | PFIZER INC. | $546.00 | 10/14/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER | No dispute reported | 06/30/2026 | 1228740366 |
| Principal investigator 1 | PFIZER INC. | $6,300.00 | 10/14/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH | A STUDY OF INTRAVESICAL ENFORTUMAB VEDOTIN FOR TREATMENT OF PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER NMIBC | No dispute reported | 06/30/2026 | 1228741504 |
| Principal investigator 1 | PFIZER INC. | $1,556.08 | 10/14/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228741954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,378.50 | 10/13/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175354842 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,107.00 | 10/10/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175354693 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $12,800.00 | 10/09/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1242061116 |
| Principal investigator 1 | PFIZER INC. | $58,339.10 | 10/09/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228740783 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $13,530.00 | 10/08/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection | No dispute reported | 06/30/2026 | 1249804252 |
| Principal investigator 1 | PFIZER INC. | $13,325.67 | 10/07/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228730682 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,163.00 | 10/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175354679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,402.00 | 10/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175354758 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,105.00 | 10/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175354784 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,260.00 | 10/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175354885 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,351.00 | 10/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175354997 |
| Principal investigator 1 | Janssen Research & Development, LLC | $431.00 | 10/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175355174 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,912.00 | 10/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175355206 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,225.00 | 10/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175355232 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 10/03/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401653 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 10/03/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401657 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 10/03/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401659 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,446.00 | 10/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175355077 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,987.00 | 10/02/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER L | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175354817 |
| Principal investigator 1 | Laborie Medical Technologies Corp. | $3,375.00 | 10/02/2025 | Non-covered Recipient Entity CURC Carolina Urologic Research Ctr LLC | PINNACLE | No dispute reported | 06/30/2026 | 1250724522 |
| Principal investigator 1 | Laborie Medical Technologies Corp. | $1,655.00 | 10/02/2025 | Non-covered Recipient Entity CURC Carolina Urologic Research Ctr LLC | PINNACLE | No dispute reported | 06/30/2026 | 1250724524 |
| Principal investigator 1 | MEDIVATION LLC. | $1,287.00 | 10/02/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228747739 |
| Principal investigator 1 | Celgene Corporation | $17,800.00 | 09/30/2025 | Non-covered Recipient Entity Carolina Urologic Research Center, Llc | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | No dispute reported | 06/30/2026 | 1222305622 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/30/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228717247 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/30/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228718471 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/30/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723754 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/29/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727167 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $42,585.58 | 09/26/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190297730 |
| Recipient | PFIZER INC. | $940.00 | 09/25/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727221 |
| Principal investigator 1 | PFIZER INC. | $2,080.00 | 09/24/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228757750 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,200.00 | 09/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234182436 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 09/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234182440 |
| Principal investigator 1 | Astellas Pharma Global Development | $300.00 | 09/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234182444 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $76,338.66 | 09/22/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) | No dispute reported | 06/30/2026 | 1190299791 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 09/22/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228716593 |
| Principal investigator 1 | MEDIVATION LLC. | $5,995.60 | 09/18/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228742553 |
| Principal investigator 1 | Organon Llc | $788.61 | 09/17/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | 3475-676 | No dispute reported | 06/30/2026 | 1173042396 |
| Principal investigator 1 | Exelixis Inc. | $5,376.00 | 09/16/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380312 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,619.00 | 09/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355113 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,884.00 | 09/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355214 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $24,826.82 | 09/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In | No dispute reported | 06/30/2026 | 1190299783 |
| Principal investigator 1 | PFIZER INC. | $1,746.36 | 09/13/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228757446 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,242.00 | 09/12/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234182438 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,971.70 | 09/12/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) | No dispute reported | 06/30/2026 | 1185542074 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $228.36 | 09/11/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | No dispute reported | 06/30/2026 | 1242061003 |
| Principal investigator 1 | Blue Earth Diagnostics | $10,000.00 | 09/10/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy | No dispute reported | 06/30/2026 | 1253758585 |
| Principal investigator 1 | PFIZER INC. | $31,655.00 | 09/09/2025 | Non-covered Recipient Entity START San Antonio LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF MEVROMETOSTAT PF06821497 WITH ENZALUTAMIDE IN METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER MEVPRO3 | No dispute reported | 06/30/2026 | 1228754406 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,009.00 | 09/08/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175354824 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,851.00 | 09/08/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355004 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,768.00 | 09/05/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270048 |
| Principal investigator 1 | Astellas Pharma Global Development | $489.00 | 09/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234182442 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $21,060.00 | 09/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410828 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $780.00 | 09/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411048 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 09/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411166 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $14,976.00 | 09/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225411472 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,184.00 | 09/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175355120 |
| Principal investigator 1 | Exelixis Inc. | $359.55 | 09/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380314 |
| Principal investigator 1 | Janssen Research & Development, LLC | $459.00 | 09/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354687 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401608 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401610 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401616 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401618 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401622 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401624 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401626 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 08/28/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401628 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 08/28/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409394 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,953.48 | 08/28/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409460 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,451.29 | 08/28/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409480 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $6,874.57 | 08/28/2025 | Non-covered Recipient Entity Inova Health Care Services | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409514 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 08/28/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409528 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $32,647.88 | 08/27/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190299787 |
| Recipient | PFIZER INC. | $3,200.00 | 08/27/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726556 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $49,004.10 | 08/26/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1190306637 |
| Principal investigator 1 | Janssen Research & Development, LLC | $459.50 | 08/25/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175354809 |
| Principal investigator 1 | PFIZER INC. | $35,508.00 | 08/22/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228787444 |
| Principal investigator 1 | PFIZER INC. | $856.26 | 08/22/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228787734 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $1,524.60 | 08/21/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | No dispute reported | 06/30/2026 | 1242060869 |
| Recipient | PFIZER INC. | $3,200.00 | 08/21/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726316 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,726.00 | 08/18/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175354794 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,112.00 | 08/18/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355136 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,716.00 | 08/18/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,404.00 | 08/18/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $173.00 | 08/18/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355284 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/18/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228717479 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 08/18/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228718592 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,277.00 | 08/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175354900 |
| Principal investigator 1 | Janssen Research & Development, LLC | $40,882.00 | 08/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175355025 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,629.19 | 08/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190306605 |
| Principal investigator 1 | PFIZER INC. | $1,556.08 | 08/13/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228786042 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,009.00 | 08/11/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175354765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,191.00 | 08/11/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175355240 |
| Recipient | PFIZER INC. | $330.00 | 08/11/2025 | Covered Recipient Physician | DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726800 |
| Principal investigator 1 | PFIZER INC. | $3,112.16 | 08/09/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228766751 |
| Recipient | Novartis Pharmaceuticals Corporation | $1,431.62 | 08/05/2025 | Covered Recipient Physician | HEOR | No dispute reported | 06/30/2026 | 1190292049 |
| Recipient | PFIZER INC. | $330.00 | 08/05/2025 | Covered Recipient Physician | DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727431 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,654.00 | 08/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354742 |
| Principal investigator 1 | Janssen Research & Development, LLC | $630.00 | 08/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354778 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,310.00 | 08/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354801 |
| Principal investigator 1 | Janssen Research & Development, LLC | $862.00 | 08/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354851 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,878.00 | 08/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175355347 |
| Recipient | PFIZER INC. | $330.00 | 08/01/2025 | Covered Recipient Physician | DISITAMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726888 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,036.00 | 08/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641782 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,132.00 | 08/01/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176641831 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,866.00 | 07/28/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175354981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,298.00 | 07/28/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175355271 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 07/28/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228716591 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,603.00 | 07/25/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175355034 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,299.00 | 07/25/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175355315 |
| Principal investigator 1 | PFIZER INC. | $5,090.80 | 07/25/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228787411 |
| Principal investigator 1 | Janssen Research & Development, LLC | $39,619.00 | 07/23/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270073 |
| Principal investigator 1 | Janssen Research & Development, LLC | $654.00 | 07/23/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270182 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $70,317.00 | 07/21/2025 | Non-covered Recipient Entity Carolina Urologic Research Center Llc | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402421 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $252.00 | 07/18/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408658 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,300.00 | 07/17/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175355278 |
| Principal investigator 1 | Exelixis Inc. | $12,744.90 | 07/16/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380310 |
| Principal investigator 1 | PFIZER INC. | $2,180.10 | 07/16/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228762357 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,768.00 | 07/14/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270207 |
| Recipient | PFIZER INC. | $330.00 | 07/11/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727219 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,626.00 | 07/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175354644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,341.00 | 07/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175354973 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,885.00 | 07/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175355092 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,452.00 | 07/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175355193 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,982.00 | 07/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175355294 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,031.00 | 07/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175355049 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,366.00 | 07/04/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355098 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $15,900.00 | 07/03/2025 | Non-covered Recipient Entity Carolina Urologic Research Center Llc | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402369 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $5,356.00 | 07/03/2025 | Non-covered Recipient Entity Carolina Urologic Research Center Llc | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402423 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 07/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228743064 |
| Principal investigator 1 | MEDIVATION LLC. | $1,287.00 | 07/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755528 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/02/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726472 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 07/01/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726390 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,836.00 | 06/30/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175355128 |
| Principal investigator 1 | PFIZER INC. | $789.10 | 06/27/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228776081 |
| Principal investigator 1 | PFIZER INC. | $2,180.10 | 06/25/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228786751 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/24/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892234 |
| Principal investigator 1 | PFIZER INC. | $800.00 | 06/24/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228761103 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,000.00 | 06/23/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,182.00 | 06/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175355018 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,899.00 | 06/20/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270037 |
| Principal investigator 1 | Janssen Research & Development, LLC | $525.00 | 06/20/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270128 |
| Principal investigator 1 | Laborie Medical Technologies Corp. | $562.50 | 06/19/2025 | Non-covered Recipient Entity CURC Carolina Urologic Research Ctr LLC | PINNACLE | No dispute reported | 06/30/2026 | 1250724526 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,841.00 | 06/16/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,446.00 | 06/16/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175355083 |
| Recipient | PFIZER INC. | $940.00 | 06/14/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228771218 |
| Principal investigator 1 | Exelixis Inc. | $10,752.00 | 06/11/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380308 |
| Principal investigator 1 | PFIZER INC. | $2,080.00 | 06/07/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228775504 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $94,520.00 | 06/06/2025 | Non-covered Recipient Entity Carolina Urologic Research Center Llc | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402373 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,312.00 | 06/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175354933 |
| Principal investigator 1 | Astellas Pharma Global Development | $489.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234182434 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $50.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892102 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892106 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,550.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892112 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,600.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892119 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $150.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892123 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $800.00 | 06/05/2025 | Non-covered Recipient Entity LANCASTER UROLOGY PC DBA KEYSTONE | ProvONE | No dispute reported | 06/30/2026 | 1247892126 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228722462 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723272 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228779733 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228780850 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791023 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791316 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791610 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792278 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792282 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 06/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793719 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401572 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401574 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401576 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401578 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401580 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401584 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401586 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401588 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401592 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 06/04/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401594 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,953.48 | 06/04/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407998 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 06/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408034 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 06/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408136 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $325.83 | 06/04/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408174 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,339.92 | 06/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408228 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,451.29 | 06/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408310 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 06/04/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408358 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,700.00 | 06/04/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | STUDY NAME# A Non-Interventional Retrospective Real-World Study to Assess Treatment Patterns, Surrogate Endpoints and Overall Survival in Muscle Invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1232935887 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $997.32 | 06/04/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with Pembrolizumab Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma KEYVIBE-010 | No dispute reported | 06/30/2026 | 1232936486 |
| Principal investigator 1 | Janssen Research & Development, LLC | $890.00 | 06/02/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175355053 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,592.00 | 06/02/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-m | No dispute reported | 06/30/2026 | 1175355376 |
| Recipient | PFIZER INC. | $940.00 | 06/01/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769180 |
| Recipient | PFIZER INC. | $940.00 | 05/31/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228751815 |
| Recipient | PFIZER INC. | $940.00 | 05/31/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228751966 |
| Recipient | PFIZER INC. | $940.00 | 05/31/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228753341 |
| Recipient | PFIZER INC. | $940.00 | 05/31/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228771236 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,138.00 | 05/29/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175355220 |
| Principal investigator 1 | PFIZER INC. | $1,746.36 | 05/29/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228772268 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $436.80 | 05/28/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407408 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $436.80 | 05/28/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407410 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,001.19 | 05/28/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407610 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $436.80 | 05/28/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407622 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $329.55 | 05/28/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225407624 |
| Recipient | Novartis Pharma AG | $1,204.70 | 05/23/2025 | Covered Recipient Physician | CAAA617B12302 | No dispute reported | 06/30/2026 | 1248109481 |
| Principal investigator 1 | Laborie Medical Technologies Corp. | $1,092.50 | 05/22/2025 | Non-covered Recipient Entity CURC Carolina Urologic Research Ctr LLC | PINNACLE | No dispute reported | 06/30/2026 | 1250724528 |
| Principal investigator 1 | PFIZER INC. | $4,360.20 | 05/22/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228773471 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $375.00 | 05/21/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401552 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $282.82 | 05/21/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401568 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $282.82 | 05/21/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225401570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $375.00 | 05/19/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269985 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,204.00 | 05/19/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269995 |
| Principal investigator 1 | Janssen Research & Development, LLC | $273.00 | 05/19/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270120 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,581.00 | 05/19/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270155 |
| Principal investigator 1 | Janssen Research & Development, LLC | $527.00 | 05/19/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270189 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,452.00 | 05/19/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175354628 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,597.00 | 05/16/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269946 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,014.00 | 05/16/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270001 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $4,839.12 | 05/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | No dispute reported | 06/30/2026 | 1242060349 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,682.00 | 05/15/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175269977 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,784.00 | 05/15/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270026 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,875.00 | 05/15/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270064 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,946.00 | 05/15/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270086 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,205.00 | 05/15/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270225 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,401.00 | 05/14/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270114 |
| Principal investigator 1 | PFIZER INC. | $1,432.60 | 05/14/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228763489 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228751376 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228752116 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228753673 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760831 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768665 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 05/12/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269922 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,598.00 | 05/12/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,014.00 | 05/12/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270166 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,770.00 | 05/12/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270174 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,652.00 | 05/12/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270197 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,215.00 | 05/12/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175354965 |
| Principal investigator 1 | MEDIVATION LLC. | $1,462.50 | 05/08/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791495 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 05/08/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791975 |
| Principal investigator 1 | MEDIVATION LLC. | $1,287.00 | 05/08/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792230 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30.00 | 05/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634094 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30.00 | 05/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176634113 |
| Principal investigator 1 | Janssen Research & Development, LLC | $862.00 | 05/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354926 |
| Principal investigator 1 | Janssen Research & Development, LLC | $33,040.00 | 05/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175355225 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 05/05/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228768714 |
| Principal investigator 1 | PFIZER INC. | $4,033.74 | 05/03/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228773284 |
| Recipient | PFIZER INC. | $330.00 | 05/01/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768259 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,293.46 | 04/30/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1185542077 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 04/29/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228755064 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 04/29/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228757024 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,301.00 | 04/28/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175269908 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48,738.00 | 04/28/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175355324 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $74,099.70 | 04/28/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1232927579 |
| Recipient | Novartis Pharma AG | $615.80 | 04/28/2025 | Covered Recipient Physician | CAAA617D12302 | No dispute reported | 06/30/2026 | 1248109479 |
| Recipient | PFIZER INC. | $940.00 | 04/27/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769429 |
| Recipient | PFIZER INC. | $940.00 | 04/26/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228751683 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,954.00 | 04/25/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175355371 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 04/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401458 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 04/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401472 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $4,500.00 | 04/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection | No dispute reported | 06/30/2026 | 1249803901 |
| Principal investigator 1 | Ortho-Clinical Diagnostics, Inc. | $39,237.00 | 04/23/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Vitros Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection | No dispute reported | 06/30/2026 | 1249803905 |
| Recipient | PFIZER INC. | $330.00 | 04/18/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228759596 |
| Principal investigator 1 | Laborie Medical Technologies Corp. | $1,655.00 | 04/17/2025 | Non-covered Recipient Entity CURC Carolina Urologic Research Ctr LLC | PINNACLE | No dispute reported | 06/30/2026 | 1250724530 |
| Principal investigator 1 | PFIZER INC. | $8,591.70 | 04/16/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228781458 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $252.00 | 04/14/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404299 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,260.00 | 04/14/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405312 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,260.00 | 04/14/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406188 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/14/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228752369 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 04/12/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751333 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 04/12/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754339 |
| Principal investigator 1 | Exelixis Inc. | $29,475.35 | 04/11/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380306 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,533.00 | 04/10/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270135 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $6,375.00 | 04/09/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 | No dispute reported | 06/30/2026 | 1232926915 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $507.00 | 04/09/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176632842 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,072.00 | 04/09/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176632987 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,126.00 | 04/09/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | No dispute reported | 06/30/2026 | 1176633008 |
| Principal investigator 1 | PFIZER INC. | $2,869.10 | 04/08/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228778977 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,577.00 | 04/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175354662 |
| Recipient | PFIZER INC. | $1,400.00 | 04/04/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228752885 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 04/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789849 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $41,907.00 | 04/02/2025 | Non-covered Recipient Entity Carolina Urologic Research Center Llc | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,907.00 | 03/31/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175355263 |
| Principal investigator 1 | Exelixis Inc. | $4,225.00 | 03/28/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380298 |
| Recipient | PFIZER INC. | $3,200.00 | 03/27/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768860 |
| Principal investigator 1 | Exelixis Inc. | $151,553.70 | 03/26/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380302 |
| Principal investigator 1 | Exelixis Inc. | $22,146.70 | 03/26/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380304 |
| Principal investigator 1 | Laborie Medical Technologies Corp. | $1,655.00 | 03/26/2025 | Non-covered Recipient Entity CURC Carolina Urologic Research Ctr LLC | PINNACLE | No dispute reported | 06/30/2026 | 1250724532 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $566.56 | 03/26/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926569 |
| Principal investigator 1 | PFIZER INC. | $61,610.52 | 03/25/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228760491 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 03/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401448 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 03/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401474 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 03/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401490 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 03/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401494 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 03/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401520 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 03/24/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401546 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 03/24/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404207 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 03/24/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405314 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 03/24/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406190 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,733.68 | 03/24/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225407186 |
| Principal investigator 1 | Exelixis Inc. | $650.00 | 03/24/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380320 |
| Principal investigator 1 | Exelixis Inc. | $16,890.00 | 03/24/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380326 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,149.00 | 03/24/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175355158 |
| Principal investigator 1 | PFIZER INC. | $72,126.30 | 03/22/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228794468 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $74,631.00 | 03/21/2025 | Non-covered Recipient Entity Carolina Urologic Research Center Llc | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402371 |
| Principal investigator 1 | PFIZER INC. | $5,088.32 | 03/21/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228783105 |
| Principal investigator 1 | PFIZER INC. | $8,720.40 | 03/21/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSEDREFRACTORY SMALL CELL LUNG CANCER SCLC CASTRATION RESISTANT PROSTATE CANCER CRPC AND FOLLICULAR LYMPHOMA FL | No dispute reported | 06/30/2026 | 1228797519 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,242.00 | 03/19/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234182432 |
| Principal investigator 1 | Exelixis Inc. | $1,500.00 | 03/17/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380322 |
| Principal investigator 1 | Exelixis Inc. | $2,000.00 | 03/17/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380330 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,442.00 | 03/17/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175354769 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $350.00 | 03/12/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | STUDY NAME# A Non-Interventional Retrospective Real-World Study to Assess Treatment Patterns, Surrogate Endpoints and Overall Survival in Muscle Invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1232935929 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,145.00 | 03/10/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175355042 |
| Principal investigator 1 | PFIZER INC. | $30,805.26 | 03/10/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228760455 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228724340 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774140 |
| Principal investigator 1 | MEDIVATION LLC. | $1,287.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774475 |
| Principal investigator 1 | MEDIVATION LLC. | $16,686.80 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774935 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775032 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775091 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775571 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775581 |
| Principal investigator 1 | MEDIVATION LLC. | $1,287.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776467 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776665 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777002 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777130 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777328 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777757 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777782 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778214 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228785600 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228785908 |
| Principal investigator 1 | MEDIVATION LLC. | $286.00 | 03/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786937 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,604.00 | 03/05/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269929 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,275.00 | 03/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630200 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $63.00 | 03/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630204 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,781.70 | 03/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630208 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $500.00 | 03/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630212 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $4,000.00 | 03/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630217 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,734.27 | 03/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630222 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630227 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $100.00 | 03/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176630232 |
| Principal investigator 1 | Janssen Research & Development, LLC | $890.00 | 03/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354620 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,626.00 | 03/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354989 |
| Principal investigator 1 | PFIZER INC. | $92,415.78 | 02/27/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228754906 |
| Principal investigator 1 | PFIZER INC. | $92,415.78 | 02/27/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228756533 |
| Recipient | PFIZER INC. | $3,200.00 | 02/27/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760745 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 02/26/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401456 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 02/26/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401496 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 02/26/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401542 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 02/26/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404209 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $780.00 | 02/26/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404301 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $14,976.00 | 02/26/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404303 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $21,060.00 | 02/26/2025 | Non-covered Recipient Entity Charleston Neuroscience Institute | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405316 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,281.60 | 02/26/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365 | No dispute reported | 06/30/2026 | 1232925769 |
| Principal investigator 1 | PFIZER INC. | $1,008.24 | 02/24/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228761205 |
| Principal investigator 1 | PFIZER INC. | $3,658.20 | 02/22/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228770740 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150,192.00 | 02/21/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269916 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,670.00 | 02/20/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,995.00 | 02/20/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270056 |
| Principal investigator 1 | Janssen Research & Development, LLC | $82,850.00 | 02/20/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270216 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,169.00 | 02/17/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175354707 |
| Recipient | PFIZER INC. | $3,200.00 | 02/15/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228771109 |
| Principal investigator 1 | Exelixis Inc. | $5,401.00 | 02/14/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380324 |
| Principal investigator 1 | Exelixis Inc. | $4,067.12 | 02/14/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380328 |
| Principal investigator 1 | Exelixis Inc. | $1,600.00 | 02/14/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380332 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,122.00 | 02/14/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175269970 |
| Recipient | PFIZER INC. | $330.00 | 02/14/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760688 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $25,202.07 | 02/13/2025 | Non-covered Recipient Entity Carolina Urologic Research Center Llc | BAY 1841788, A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical | No dispute reported | 06/30/2026 | 1225402375 |
| Principal investigator 1 | Genentech, Inc. | $4,555.00 | 02/13/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase III Ipatasertib plus abiraterone in mCRPC 1st Line | No dispute reported | 06/30/2026 | 1211583996 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,558.00 | 02/13/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270097 |
| Recipient | PFIZER INC. | $940.00 | 02/13/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228751990 |
| Recipient | PFIZER INC. | $940.00 | 02/13/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228759802 |
| Recipient | PFIZER INC. | $940.00 | 02/13/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760484 |
| Principal investigator 1 | Exelixis Inc. | $13,064.00 | 02/10/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380300 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,086.00 | 02/10/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175354725 |
| Principal investigator 1 | Eli Lilly and Company | $8,401.03 | 02/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) | No dispute reported | 06/30/2026 | 1187878585 |
| Principal investigator 1 | PFIZER INC. | $1,008.24 | 02/06/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228760077 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 02/06/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | A PHASE 3 RANDOMIZED OPENLABEL STUDY OF PF06821497 MEVROMETOSTAT IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE MEVPRO1 | No dispute reported | 06/30/2026 | 1228768881 |
| Principal investigator 1 | Exelixis Inc. | $846.00 | 02/05/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222380334 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 02/03/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401498 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,828.50 | 02/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175354717 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,752.00 | 02/03/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175354874 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $33,210.24 | 02/03/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-365 | No dispute reported | 06/30/2026 | 1232925939 |
| Recipient | PFIZER INC. | $940.00 | 02/03/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228751656 |
| Recipient | PFIZER INC. | $940.00 | 02/03/2025 | Covered Recipient Physician | ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770631 |
| Principal investigator 1 | AstraZeneca UK Limited | $762,065.50 | 01/31/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) | No dispute reported | 06/30/2026 | 1185542072 |
| Recipient | Novartis Pharma AG | $509.29 | 01/30/2025 | Covered Recipient Physician | CAAA617D12302 | No dispute reported | 06/30/2026 | 1248109477 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $245,681.01 | 01/29/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco | No dispute reported | 06/30/2026 | 1185542080 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,233.05 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401446 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401454 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,233.05 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401468 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,233.05 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401482 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401484 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,233.05 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401486 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,233.05 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401492 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,233.05 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401514 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401516 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,233.05 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401518 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,233.05 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401526 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 01/29/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401528 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760631 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760721 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768984 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769246 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769843 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | SASANLIMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769917 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770404 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | PF06821497 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770589 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,943.33 | 01/27/2025 | Covered Recipient Teaching Hospital Karmanos Cancer Hospital | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225401470 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,953.48 | 01/27/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403357 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,173.00 | 01/27/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NM | No dispute reported | 06/30/2026 | 1175354892 |
| Principal investigator 1 | PFIZER INC. | $2,080.00 | 01/25/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228801327 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,000.00 | 01/24/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175355071 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $154,783.81 | 01/22/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1190306639 |
| Principal investigator 1 | PFIZER INC. | $92,415.78 | 01/21/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228754910 |
| Principal investigator 1 | PFIZER INC. | $92,415.78 | 01/21/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228757373 |
| Principal investigator 1 | Eli Lilly and Company | $3,000.00 | 01/16/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS | No dispute reported | 06/30/2026 | 1187878695 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $257.88 | 01/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In | No dispute reported | 06/30/2026 | 1190306601 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,682.10 | 01/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | No dispute reported | 06/30/2026 | 1190306603 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $46,678.46 | 01/15/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) | No dispute reported | 06/30/2026 | 1190306635 |
| Principal investigator 1 | PFIZER INC. | $7,959.90 | 01/15/2025 | Non-covered Recipient Entity Carolina Urologic Research Center LLC | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATIONSENSITIVE PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228798305 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,599.00 | 01/14/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175270103 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,122.00 | 01/13/2025 | Non-covered Recipient Entity Carolina Urologic Rsrch Ctr | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175270020 |
| Recipient | Novartis Pharmaceuticals Corporation | $7,425.55 | 01/13/2025 | Covered Recipient Physician | HEOR | No dispute reported | 06/30/2026 | 1190292054 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 01/13/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754177 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 01/12/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754180 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 01/12/2025 | Non-covered Recipient Entity Carolina Urologic Research Center | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756242 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $688,758.90 | 01/08/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER, LLC | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185542082 |
| Principal investigator 1 | Astellas Pharma Global Development | $978.00 | 01/07/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | No dispute reported | 06/30/2026 | 1234182430 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,040.00 | 01/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175354869 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,587.00 | 01/06/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions | No dispute reported | 06/30/2026 | 1175355253 |
| Principal investigator 1 | Janssen Research & Development, LLC | $129,696.00 | 01/02/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175354733 |
| Principal investigator 1 | MEDIVATION LLC. | $1,287.00 | 01/02/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774967 |
| Principal investigator 1 | MEDIVATION LLC. | $1,125.50 | 01/02/2025 | Non-covered Recipient Entity CAROLINA UROLOGIC RESEARCH CENTER LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777483 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $0.00 | 2 |
| PY2024 | Value of interest | $4,471,851.45 | 2 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $1,458,965.61 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $704,328.23 | 1 |
| PY2021 | Amount invested | $503,091.59 | 1 |
| PY2021 | Value of interest | $654,019.10 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
5 records · PY2021–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | SN Holdings, LLC | $0.00 | $17,278.77 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124771677 |
| PY2024 | SN Holdings, LLC | $0.00 | $4,454,572.68 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124773425 |
| PY2023 | SN Holdings, LLC | $0.00 | $1,458,965.61 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1032887523 |
| PY2022 | SN Holdings, LLC | $0.00 | $704,328.23 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 941609497 |
| PY2021 | SN Holdings, LLC | $503,091.59 | $654,019.10 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 820125429 |